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Mutation in leucine-rich-repeat kinase 2 (LRRK2) is a common
cause of Parkinson disease (PD). A disease-causing point mutation
R1441H/G/C in the GTPase domain of LRRK2 leads to overactivation
of its kinase domain. However, the mechanism by which this mu-
tation alters the normal function of its GTPase domain [Ras of
complex proteins (Roc)] remains unclear. Here, we report the effects
of R1441H mutation (RocR1441H) on the structure and activity of Roc.
We show that Roc forms a stablemonomeric conformation in solution
that is catalytically active, thus demonstrating that LRRK2 is a bona
fide self-contained GTPase. We further show that the R1441H muta-
tion causes a twofold reduction in GTPase activity without affecting
the structure, thermal stability, and GDP-binding affinity of Roc. How-
ever, the mutation causes a twofold increase in GTP-binding affinity
of Roc, thus suggesting that the PD-causing mutation R1441H traps
Roc in a more persistently activated state by increasing its affinity for
GTP and, at the same time, compromising its GTP hydrolysis.
neurodegenerative disease | dimer | monomer | oligomeric states
Mutation in leucine-rich-repeat kinase 2 (LRRK2) is acommon cause of Parkinson disease (PD) (1–5). LRRK2 is
a large (2,527-aa) multidomain protein consisting of seven pu-
tative domains (2), including a Ras-like GTPase domain called Ras
of complex proteins (Roc), followed by a domain called C-terminal
of Roc (COR), which is then followed by a kinase domain (Kin).
It remains unclear how perturbations of these activities result in
disease; however, the most common mutation in LRRK2-associ-
ated PD, G2019S in the kinase domain, shows higher kinase ac-
tivity than wild type; therefore, its overactivation might be associ-
ated with disease pathogenesis (6).
The tandem Roc-COR-Kin arrangement suggests that their
activities might be coupled such that the GTPase activity of Roc
might modulate the kinase activity. Indeed, several studies have
shown that GTP binding to the Roc domain regulates the activity
of the Kin domain (7, 8). Moreover, a PD-associated mutation in
the Roc domain (R1441C) has been shown to have higher kinase
activity (9), thus suggesting that mutations in the Roc domain,
also up-regulate kinase activity.
Understanding the function of Roc and its mechanism of ac-
tion is important for understanding the mechanism of PD path-
ogenesis and therapeutic development. However, because of the
lack sufficient quantity of protein samples amendable for detailed
investigations, the biochemical properties and enzymatic activities
of the Roc domain of LRRK2 are poorly understood.
Here, we describe a stably folded construct of human Roc
domain that enabled us to investigate quantitatively its bio-
chemical and enzymatic properties. The results revealed that
a PD-causing mutation R1441H in the Roc domain renders it
less active at hydrolyzing GTP, as well as having higher affinity
for GTP, than its wild-type counterpart, thereby increasing the
residence time of its GTP-bound “active state,” which is associ-
ated with PD pathogenesis (8).
Results and Discussion
Construction of a Stable Human LRRK2 Roc Domain. A construct of
the Roc domain of LRRK2 has been previously reported to form
a constitutive domain-swapped dimer (10). However, this is cur-
rently controversial because of the unusual domain-swap con-
formation and that such a dimer has not been demonstrated in
solution. It has been suggested that the domain-swapped human
Roc structure might have been an artifact of crystallization (11);
however, we felt that this unusual structure might have been
caused by the short flanking boundaries of the construct (residues
1333–1516). To design longer Roc constructs with extended N
and C termini, we superimposed the human Roc structure [Pro-
tein Data Bank (PDB) ID code 3D6T] with an orthologous
Chlorobium tepidumRoc-Cor structure (PDB ID code 3DPU) for
comparisons. The most significant difference between the two
structures is the topologies of the N terminus relative to the C
terminus in each structure. In the human structure, the N ter-
minus Cα is ∼33.6 Å from the C terminus and pointing away from
each other (Fig. S1A). In contrast, in the C. tepidum structure, the
N and C termini are closely packed together (Cα-Cα distance of
∼5.5 Å) via backbone H bonding that forms a small hydrophobic
patch (Fig. S1B).
Significance
Mutations in the gene encoding for leucine-rich-repeat kinase
2 (LRRK2) are a common cause of Parkinson disease (PD). To
understand how LRRK2 causes PD, we need to understand its
normal functions and how they are altered by disease-causing
mutations. This effort has been hampered by the lack of ap-
propriate samples, which led to some confusion in the field.
This study shows the construction of a stably folded domain of
LRRK2 called Ras of complex proteins (Roc). We use the study
to resolve two conflicting models of Roc oligomerization by
quantitatively demonstrating its GTPase activity in both mo-
nomeric and dimeric states. We further show that a PD-causing
mutation affects both GTP binding and GTPase activity of Roc.
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To determine whether this contact patch occurs in human
LRRK2, we built a homology model of human Roc domain with
extended termini spanning the residues predicted to be in the
hydrophobic patch. Our homology model revealed a similar hy-
drophobic patch that consists of two contiguous segments, resi-
dues 1329–1332 and 1518–1524, at the N- and C-terminal ex-
tensions, respectively (Fig. 1). Visually, this patch appears to act
as the “glue” that bonds the N- and C-terminal extensions to-
gether and would prevent a domain-swapped dimer from occur-
ring. To investigate whether the patch affects the structure of
Roc, we made a series of human Roc constructs with the N and C
termini extending into the hydrophobic patch. A resulting con-
struct consisting of residues 1329–1520 was highly stable and
amendable for biochemical and biophysical experimentations.
Roc Domain Forms Stable Monomers. We expressed our terminal-
extended Roc construct (Rocext) in Escherichia coli and purified it by
sequentially passing it through a column containing Nickel-nitrilo-
triacetic acid (Ni-NTA), followed by size-exclusion chromatography.
During the final step of purification, we noticed that Rocext eluted
from the Superdex 200 column in two separate peaks (Fig. 2A). The
first peak (at 91.8 mL) corresponded to a molecular mass of about
48 kDa (Roc48), and the second peak (at 98.7 mL) corresponded to
about 24 kDa (Roc24) based on column calibration standard curve
using the manufacturer’s molecular mass standard kit. The theo-
retical mass of Rocext is 23.5 kDa, so Roc24 and Roc48 appear to
represent the monomeric and dimeric conformations of Rocext, re-
spectively. Consistent with this, Roc24 and Roc48 resolved identically
on reducing SDS/PAGE with an apparent molecular mass of ∼24
kDa, and they both reacted with antibodies against LRRK2 on
Western blots (Fig. 2 B and C).
To further authenticate our construct and to determine their
precise molecular masses, we used matrix-assisted laser desorption/
ionization time of flight (MALDI-TOF) mass spectrometry (MS).
We detected a single mass of 23,484 Da in the Roc24 sample and
46,839 Da in the Roc48 sample, which correspond to the molecular
masses of monomeric and dimeric forms of Rocext, respectively
(Fig. 2 E and F).
To further confirm that the molecular masses determined by
MS occur in solution, we used multiangle light scattering coupled
with size-exclusion chromatography (SEC-MALS) to determine
the molecular masses of Roc24 and Roc48 in solution. Roc24
resolved on SEC-MALS as a single peak with a calculated mo-
lecular mass of 25 ± 2 kDa, whereas Roc48 resolved as a single
peak with a molecular mass of 46 ± 2 kDa, again consistent with
the molecular mass of Rocext monomer and dimer within in-
strumental errors (Fig. 2D). These results confirm the existence
of monomeric and dimeric Rocext in solution in the absence of
a Cor domain.
The existence of Rocext as both dimers and monomers in so-
lution indicate that it does not form constitutive dimer as pre-
viously suggested (10, 11). This gives rise to the possibility of
a dynamic nucleotide-dependent dimerization as a regulation
mechanism of Roc activity suggested by Gotthardt et al. (11). To
investigate this possibility, we determined whether Roc48 changes
its conformation upon binding to guanine nucleotides by incu-
bating Roc48 with GDP or GppNHp for 2 h using standard nu-
cleotide-exchange procedures (12). As shown in Fig. 3A, virtually
all of Roc48 was converted to Roc24 upon binding either GDP or
Fig. 1. Cartoon model of extended GTPase domain (Rocext). Shown is
a homology model of our GTPase domain spanning residues 1329–1520 built
based on the structure of bacterial Roc-Cor structure (PDB ID code 3DPU).
The N and C terminals are labeled N and C, respectively. Arrows indicate the
locations of terminals of previously determined structure of human GTPase
domain (PDB ID code 3D6T). Colored gray are hydrophobic residues that
form a hydrophobic patch gluing N and C terminal together.
Fig. 2. Oligomeric states of Rocext in solution. (A) Size-exclusion chroma-
tography elution profile of purified Rocext showing two peaks (48 and 24)
that correspond to molecular masses of ∼48 and ∼24 kDa, respectively, based
on standard calibration curve. (B) SDS/PAGE of peaks from A, 48 and 24.
Molecular mass standards are labeled in kilodaltons to the left of the marker
lane (MW). (C) Western blot of peaks from A, 48 and 24. Molecular mass
standards are labeled in kilodaltons to the left of the marker lane (MW). (D)
SEC-MALS profile of purified Rocext showing two peaks [48 (black solid line)
and 24 (black dashed line)], along with their average molecular mass cal-
culated from light scattering (blue and red lines, respectively). (E and F)
MALDI-TOF MS spectra of 48 and 24, respectively.
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GppNHp. We again used SEC-MALS to confirm that this is a
bona fide conversion of dimers into monomers (Fig. 3B).
At the onset, we anticipated that dimer–monomer equilibrium
might be regulated by GTP/GDP cycling; however, this was not
the case because we found that GDP and GTP analog both con-
verted the dimers into monomers with equal potency. Moreover,
the physiological concentrations of guanine nucleotides (∼500 μM
GTP and ∼50 μM GDP) are higher than needed for the conver-
sion, which would render Rocext mostly monomeric; therefore, the
observed dimer–monomer conversion of Rocext is unlikely to be
physiologically relevant. For this reason, our focus turned to un-
derstanding the structure and function of the monomeric Roc24.
Monomeric Roc24 Is Catalytically Active. The literature currently
suggests that dimerization of Roc is required for its GTPase
activity (10, 11), but this requirement is uncertain because one of
the two structures that provided this insight showed an unusual
domain-swapped conformation not seen in other GTPases, whereas
the second structure required intermolecular exchange of an argi-
nine residue in trans to constitute an active site, but the required
arginine does not exist in human LRRK2 (11). Having created a
stable monomeric Roc construct enabled us to test these require-
ments. First, we set out to determine whether Roc24 has the ability
to hydrolyze GTP to generate GDP by using normal-phase hydro-
philic interaction liquid chromatography (HILIC) HPLC coupled to
electrospray mass-spectrometry (LC/MS). GTP and GDP resolved as
two well separated peaks with determined molecular mass of 524 and
444 Da, which correspond to the theoretical molecular mass of GTP
(523 Da) and GDP (443 Da), respectively (Fig. S2). As shown in Fig.
4A, the production of GDP increased in a concentration-dependent
manner, thus indicating that GTP was being converted to GDP.
To understand the GTPase activity of Roc24 in more detail, we
determined its steady-state kinetic parameters using the EnzCheck
assay kit (Molecular Probes). Initial velocities were measured as
a function of GTP concentrations. The resulting saturation curve
adheres to the simple Michaelis–Menten equation, which allowed
us to calculate the steady-state kinetic parameters by nonlinear
least-squares fit using the software Prism6 (GraphPad). As sum-
marized in Fig. 4B, kcat = 0.020 ± 0.001 min
−1 and Km = 553 ± 94
μM. The low turnover rate and high Km indicate that isolated
Rocext is a slow enzyme and suggest that it might require activating
and/or exchanging factors to efficiently hydrolyze GTP.
G proteins that cycle between GTP-bound (active) and GDP-
bound (inactive) states as a switching mechanism commonly have
low intrinsic GTPase activity. Ras, for example, has equally low
intrinsic GTPase activity (kcat = 0.028 min
−1) (13). The conversion
between GDP and GTP by Ras family GTPases is usually acceler-
ated by guanine nucleotide exchange factors (GEFs), GTPase acti-
vating proteins (GAPs), or oligomerization-induced conformational
changes (14, 15). The low kcat observed for Rocext is in line
with the intrinsic activity of this family of enzymes; however,
strong activating or exchange factors of LRRK2 have not yet
been identified.
The Michaelis constant Km (which is defined as the rate of
dissociation of the enzyme–substrate complex [ES] k-1 plus the
rate of forming the product and free enzyme [P and E] k+2 di-
vided by the rate of substrate binding to enzyme forming [ES] k+1;
Km = (k+2 + k-1)/k+1) is commonly used to approximate the af-
finity of the substrate with the enzyme Kd (defined as [E][S]/[ES]).
When the chemical process is fast, the Km approximates Kd.
However, GTPases are usually slow at hydrolyzing its substrate
(represented by the rate constant k+2) and commonly bind their
product GDP with higher affinity than their substrate GTP. This
results in slow dissociation of the enzyme–product complex [EP]
and renders the Km unrepresentative of the Kd for GTP. To es-
timate the affinity of Rocext for GTP, we determined the Kd of
Rocext for GTP nonhydrolyzable analog GTPγS using a fluores-
cence polarization (FP) assay (16, 17). As shown in Fig. 5A, the
dissociation constant (Kd) of BODIBY-FL-GTPγS is 7.85 μM,
which is two orders of magnitude lower than the Km, thus con-
firming that the Km does not represent Kd in this case. Note that
we used BODIBY-FL-GTPγS instead of GTP to avoid compli-
cations associated with GTP hydrolysis during the binding assay
as commonly used in the field. Although the FP assay that we
used is well established, to confirm that the binding of BODIBY-
FL-GTPγS is an appropriate approximation of GTP binding, we
titrated Rocext prebound with BODIPY-FL-GTPγS with un-
labeled natural GTP. We found that GTP effectively displaced
BODIPY-FL-GTPγS (Fig. 5B), thus confirming that BODIPY-
FL-GTPγS binds to the same site as natural GTP on Rocext.
The affinity of Rocext with GTP in the low-micromolar range is
relatively weak compared with typical small GTPases (which are
in the sub-nanomolar range), but it is similar to that of large
GTPase dynamin family (which are in micromolar range) (18).
The weak affinity of Rocext for nucleotide and the relatively
small difference in its affinity for GTP vs. GDP (7.85 vs. 0.47 μM)
suggests that it might not require GEFs for nucleotide-exchange
cycling (physiological concentrations of GTP and GDP are ∼500
and ∼50 μM, respectively) (19). However, its low turnover rate of
0.02 molecules per minute suggests that it could require an ac-
tivation factor for efficient hydrolysis of GTP, as observed in
other GTPases.
Conformations of GDP- and GppNHp-Bound Roc. GTPases typically
function as molecular switches that toggle on/off by undergoing
conformational changes upon binding GTP and GDP. Thus, by
analogy, the Roc domain of LRRK2 is believed to regulate its
kinase domain via a similar mechanism. To investigate this, we
characterized the structure of Rocext by using circular dichroism
Fig. 3. Conversion of Roc48 to monomers upon guanine nucleotide binding.
(A) Size-exclusion chromatography profile of Roc48 apo state (green, ∼48
kDa), GDP-bound (blue, ∼24 kDa), and GppNHp-bound (red, ∼24 kDa) shows
conversion of the Roc48 peak into Roc24 peaks upon binding to either GDP or
GTP. (B) SEC-MALS profile of GDP- and GppNHp-bound Rocext with calcu-
lated molecular masses of 25 kDa for both (black line on the peak).
Fig. 4. GTPase activity of Rocext. (A) Background-subtracted LC/MS spectra of
GDP generated by Rocext GTP hydrolysis activity. Reaction was conducted with
a range of GTP concentrations (0.1–1 mM). This graph shows proportional
production of GDP with respect to the concentration of GTP. (B) Steady-state
kinetics of Rocext GTP hydrolysis. Data (open circles) is an average of three
independent measurements with error bars (± SEM) indicated.
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(CD) spectroscopy to determine the secondary structure con-
tents of Rocext bound with GDP and GppNHp (nucleotide free
Rocext is not stable and therefore was not characterized). We
observed only small structural differences between the two
forms, which are composed of 41% and 46% α-helix in its GDP-
and GppNHp-bound forms, respectively (Fig. 6A). This result
suggests that the switching mechanism does not involve large
structural changes. This is consistent with other small GTPase
where GDP/GTP cycling typically causes conformational changes
in two small loop regions, known as switch 1 and switch 2 (20, 21).
However, in large GTPases, the small conformational changes in
the switch regions lead to large global structural rearrangements.
For example, GTP hydrolysis by the GTPase domain of dynamin1
causes large conformational changes to helical domains in its N
and C termini (called NGTPase and CGTPase) to provide the me-
chanical forces necessary for pinching off invaginated coated pits
(22, 23). Interestingly, our homology model of LRRK2 also shows
flanking structures similar to NGTPase and CGTPase, which suggests
that the GTPase domain of LRRK2 could potentially function in
a similar manner.
Roc Carrying PD Mutation Has Lower GTPase Activity than Wild Type.
After establishing that the Roc domain of LRRK2 is as a bona
fide self-contained GTPase, we turned our focus to investigate
how the PD-causing mutation in Roc R1441H (RocR1441H) af-
fects its properties. We introduced the mutation by using PCR-
based site-directed mutagenesis using our Rocext DNA template
and confirmed by DNA sequencing. Protein expression and pu-
rification procedures are as described for Rocext above. The
mutated amino acid sequence was authenticated by mass spec-
trometry (Fig. S3).
We determined the GTPase activity of RocR1441H using the
same EnzCheck assay described above and compared it to wild-
type Rocext. We found that RocR1441H showed significantly lower
activity than Rocext (Fig. 7A), suggesting that the point mutation
does indeed change the GTPase activity of LRRK2 and might
constitute a basis for PD pathogenesis. This is consistent with
previously reported observations of two other amino acid sub-
stitutions at 1441 (R1441C and R1441G) using proteins pulled
down from rat brains (24).
To investigate the GTPase activity of RocR1441H in more de-
tail, we determined its enzyme kinetics. We found that it is more
than twofold less active than Rocext with kcat = 0.009 vs. 0.020
min−1, respectively, with Km = 112 ± 22 μM (Fig. 7B), suggesting
that the point-mutation R1441H affects both GTP-binding af-
finity, as well as its biochemical hydrolysis, which would un-
doubtedly trap Roc in a more persistent active state. GTP-bound
state of Roc has been shown to activate kinase activity of
LRRK2, which is associated with PD pathogenesis (8, 25).
RocR1441H Has Higher Affinity for GTP than Wild Type. To understand
how the R1441H mutation led to a reduction in GTPase activity
of Roc, we performed a battery of biochemical assays to examine
its effects on structural features, thermal stability, and guanine
nucleotide-binding affinity. We found that the point mutation
dose not affect the structure or thermal stability of Roc (Figs. 6B
and 8A), thus suggesting that the reduction in GTPase activity of
the mutant might be caused by biochemical perturbations as op-
posed to structural.
When we compared guanine nucleotide-binding affinity of
RocR1441H with Rocext using a fluorescence polarization assays as
described above, we found no significant difference in their af-
finity for GDP (Fig. 5D). However, the GTPγS-binding affinity
of RocR1414H is twofold higher than that of Rocext, Kd = 3.39 vs.
7.85 μM, respectively (Fig. 5C). This seems counterintuitive be-
cause higher substrate affinity usually results in higher activity
instead of lower as we observed.
To confirm the observed difference in GTP-binding affinity,
we determined the thermal denaturation of Rocext and RocR1441H
bound with GDP and GppNHp using differential scanning fluo-
rimetry (26). We found no significant difference in the denaturation
curve between GDP-bound RocR1441H and Rocext, which is con-
sistent with their similar affinities for GDP (Fig. 8B). How-
ever, GppNHp-bound RocR1441H has a melting temperature (Tm)
∼3.1 °C higher than Rocext, thus confirming the above observation
that the R1441H mutation does indeed lead to increased GTP-
binding affinity. More importantly, the observed increase in GTP-
binding affinity and decreased in GTPase activity would indepen-
dently result in a prolonged active state of Roc, having both features
in a single mutation is a “double-whammy” that together would trap
Roc in a more persistent active state.
Conclusions
Over the past 10 y, the field has been pursuing disparately to
understand the functions of LRRK2 and how it is affected by
Fig. 5. Guanine nucleotide-binding affinity. (A) BODIPY-FL-GTPγS–binding
affinity to RocWT was measured using FP assay. Data represented an average
of triplicates with error bars (SEM) shown. The dissociation constant (KD) was
determined by fitting nonlinear curve regression using GraphPad Prism 6. (B)
Competition of prebound BODIPY-labeled GTPγS titrated with natural un-
labeled GTP showed that the BODIPY-labeled nucleotide binds to the same
site on RocWT as natural nucleotide. (C) BODIPY-FL- GTPγS–binding affinity
to RocR1441H was measured using FP assay. Data represented an average of
triplicates with error bars (SEM) shown. The dissociation constant was de-
termined as above. (D) BODIPY-FL-GDP–binding affinity to RocWT and
RocR1441H was measured using FP assay, and the dissociation constant was
determined as above.
Fig. 6. Structure characteristic of RocWT and RocR1441H. (A) CD spectra of
RocWT bound to GDP (solid line) or GppNHp (dashed line) showed no signif-
icant difference between two forms. (B) CD spectra of RocR1441H (solid line)
and RocWT (dashed line) showed no significant difference between them.
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PD-associated mutations. A major hurdle in the field has been
the difficulty in obtaining sufficient quantity and quality of
samples (both full-length and individual domains) suitable for
quantitative investigations. We have produced a suitable Roc
domain of LRRK2 that enabled us to quantitatively demonstrate
that the Roc domain of LRRK2 is a bona fide GTPase, which
clarifies a current confusion in the field regarding the necessity
of dimerization for Roc activity. The kinase activity of LRRK2
has been shown to be overactivated in PD-associated R1441H
mutant; here, we show that it traps Roc in a more persistently
activated state by increasing its affinity for GTP and, at the same
time, decreasing its GTPase activity, thus providing insights into
the mutant’s mechanism of PD pathogenesis.
Methods
HomologyModeling.Homologymodels of human LRRK2GTPase domainwere
built based on the structure of C. tepidum Roco (PDB ID code 3DPU) by using
the programModeler 9.12 (Andrej Sali, University of California, San Francisco,
CA). Molecular graphics display and presentation were made using PyMol
(www.pymol.org).
Protein Expression and Purification. An extended GTPase domain of LRRK2
consisting of residues 1329–1520 (Rocext) was subcloned into a pETDuet-1
vector (Novagen, Merck) using PCR cloning techniques. The resulting protein
consisting of an N-terminal hexahistidine tag was expressed from Rosetta2
(DE3) E. coli (Novagen) by inducing with 0.5 mM isopropyl-β-D-thiogala-
ctopyranoside for 16 h at 20 °C. Cells harvested by centrifugation and lysed
by sonication in buffer containing 10 mMHepes (pH 7.4), 250 mM NaCl, 10 mM
magnesium acetate (MgAc), 10 mM glycine, 20 mM imidazole, 10 μM GDP, and
5% (vol/vol) glycerol. Cell debris was cleared by ultracentrifugation at 35,000
rpm in a Beckman 70Ti rotor. The supernatant was incubated with Ni-NTA
Agarose (Life Technologies) for 2 h at 4 °C, then washed with lysis buffer (de-
tailed above), and eluted with buffer containing 10 mM Hepes (pH 7.4), 250
mM NaCl, 10 mMMgAc, 10 mM glycine, 300 mM imidazole, 1 mM DTT, 10 μM
GDP, and 5% glycerol. The purified protein was then “polished” by passing
through a size-exclusion column (Superdex 200; GE Healthcare) in buffer
containing 10mMHepes (pH 7.4), 150 mMNaCl, 10 mMMgAc, 10 mMglycine,
1 mM DTT, and 5% glycerol. The purified protein was then concentrated to
∼10 mg/mL, flash frozen in liquid nitrogen, and stored at −80 °C.
Western Blotting. A polyclonal antibody against the Roc domain of human
LRRK2 (residues 1329–1520) was purchased from Cocalico Biologicals. A sec-
ondary antibody, IRDye 680RD Goat anti-rabbit, was purchased from LI-COR
Biosciences. Roc48 and Roc24 were collected from Roc48 peak and Roc24 peak
separately and loaded into SDS/PAGE. Protein bands were detected by the pri-
mary antibody and secondary antibody sequentially, and final membrane was
scanned by using an ODYSSEY Infrared Imaging System (LI-COR Biosciences).
SEC-MALS. To determine the absolutemolecular mass of Rocext in solution, we
used multiple angle light scattering. Our experimental setup includes an
AKTA FPLC (GE Healthcare Biosciences) with a silica-based size-exclusion
chromatography column (WTC-030S5; Wyatt Technology) as an LC unit.
Down from the LC is a refractive index detector (Optilab T-rEX; Wyatt
Technology), followed by a multiple light scattering detector (Dawn HeleosII;
Wyatt Technology) for determining protein concentration and particle size,
respectively. Each sample injection consisted of ∼1 mg of purified Rocext in
buffer containing 10 mM Hepes (pH 7.4), 0.15 M NaCl, 10 mM MgAc, 10 mM
glycine, 1 mMDTT, and 5% glycerol. Flow rate was set at 0.4 mL/min, and data
were collected every 2-s interval. Data processing and analysis were performed
using the ASTRA software (Wyatt Technology).
Mass Spectrometry. Molecular masses of Roc48 and Roc24 were determined
using MALDI-TOF (AB Sciex). Protein samples were desalted by using ZipTip-
C18 columns (EMD MILLIPORE) and eluted with acetonitrile; 1.5 μL of eluent
was spotted on a stainless steel MALDI plate and allowed to dry. A “sandwich”
of sample–matrix–sample was formed by layering 1.5 μL of matrix [sinapinic
acid (stock, 10 mg/mL) in 75% acetonitrile and 0.1% TFA] on top of the dried
protein sample spot, followed by another layer of protein sample on top of
the dried matrix. Sample was analyzed using standard MALDI-TOF methods.
To determine GTPase activity of Rocext byMS, we used normal-phase ZIC-HILIC
(EMD Millipore) HPLC coupled to electrospray MS; 20 μM Rocext was incubated
with various concentration of GTP (0.1, 0.2, 0.4, and 1 mM) at 25 °C for 1 h. After
incubation, protein samples were be denatured at 100 °C for 10min, followed by
centrifuging to remove denatured protein. Samples were loaded into ZIC-HILIC
HPLC equilibrated in 90% acetonitrile and 30 mM ammonium acetate and
eluted in 70% acetonitrile and 30 mM ammonium acetate isocratically. The
eluted nucleotides molecular mass was determined by inline electrospray MS.
CD Spectroscopy. CD spectra were collected on a Biologic Science Instruments
MOS450 AF/CD spectrometer with slit width of 1.0mmand data acquisition of
1.0 s. The protein samples with concentrations ranging from 0.46 to 0.86
mg/mL (based on absorbance at 280 nm) were dissolved in the buffer con-
taining 10 mM Tris·HCl (pH 7.4), 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, and
5% glycerol. The data used for graphical presentation and analyses were
each an average of five different scans.
Fluorescence Polarization Nucleotide-Binding Assay. To estimate the binding
affinity of guanine nucleotides, BODIPY-FL-GTPγS (100 nM) or 150 nM
BODIPY-FL-GDP (150 nM) (Life Technologies) were titrated with Rocext
(starting at 0.1 μM) until saturation was reached (15 and 10 μM, respectively).
Fluorescence polarization was read using an EnVison 2102 Multilabel Plate
Reader (Perkin-Elmer) with excitation at 485 nm and emission at 535 nm.
Experiments were performed at 25 °C in buffer 10 mMHepes (pH 7.4), 150 mM
NaCl, 10 mMMgAc, 10 mM glycine, 4 mM EDTA, 1 mMDTT, 5% glycerol. Data
were analyzed using Prism 6 (GraphPad Software).
Fig. 7. GTPase activity of RocR1441H. (A) Time course (1 h) GTPase activity
assayed showing RocR1441H (filled triangle with solid line) is less active than
RocWT (open circle with dashed line). (B) Steady-state kinetics of RocR1441H
GTP hydrolysis confirming that RocR1441H has a lower activity than RocWT.
Data (open circle) are averages of three independent measurements with
error bars (SEM) indicated.
Fig. 8. RocWT and RocR1441H thermal stability determined by ThermoFluor
assay. (A) Melting curve showing that RocWT (opened circle) and RocR1441H
(X) have similar Tm values in nucleotide-free forms. (B) Melting curve of
GDP-bound RocWT and RocR1441H showing similar thermal stability. (C)
Melting curve of GppNHp-bound Roc showing that RocR1441H is more ther-
mally stable than RocWT, indicative of a higher affinity of RocR1441H for GTP.
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GTPase Activity Assay. GTPase activity of Rocext was assessed by using the
Enzcheck assay kit (Life Technologies) according to manufacturer’s instruc-
tions. Briefly, Rocext (15 μM) was incubated with different concentration of
GTP (0.15, 0.3, 0.45, 0.75, 1.5, and 3 mM) in in buffer containing 10 mM
Hepes, 150 mM NaCl, 10 mM MgCl2, 1 mM DTT, and 5% glycerol at 25 °C.
Absorbances at 360 nm were recorded every 4 min for a duration of 60 min
using a microplate reader. The amount of inorganic phosphate released
from GTP hydrolysis at each time point was determined by extrapolation
using a phosphate standard curve. Kinetic parameters were determined by
fitting the data to Michaelis–Menten equation using GraphPad Prism 6.
Fluorescence Polarization-Based Nucleotide Competition Assay. To ensure that
the binding that we observed between GTP/GDP and Rocext was mediated by
the nucleotides and not the BODIPY molecules attached to them, we per-
formed nucleotide-competition assays for each nucleotide. Rocext (2 μM) was
preincubated with 100 nM BODIPY-FL-GTPγS or 150 nM BODIPY-FL-GDP (Life
Technologies) for 10 min at 25 °C in 384-wells black plate (NUNC). Then, the
Rocext–BODIPY–nucleotide complex was titrated with unlabeled natural GTP
or GDP (started at 25 nM) until the binding between Rocext and labeled
nucleotide was inhibited completely (20 μM). The fluorescence polariza-
tion was read in an EnVison 2102 Multipliable Plate Reader (Perkin-Elmer)
using excitation at 485 nm and emission at 535 nm. Experiments were
performed at 25 °C in buffer containing 10 mM Hepes (pH 7.4), 150 mM
NaCl, 10 mM MgAc, 10 mM glycine, 4 mM EDTA, 1 mM DTT, 5% glycerol.
The titration plots were fitted in a nonlinear regression curve using GraphPad
Prism 6.
ThermoFluor Assay. Solutions of 7.5 μL of 16× Sypro Orange (prepared from
5,000× stock concentrate; Life Technologies) in buffer containing 10 mM
Hepes (pH 7.4), 0.15 M NaCl, 10 mM MgAc, 10 mM glycine, 1 mM DTT, and
5% glycerol, 12.5 μL of 4 mM GDP or GppNHp (Sigma), and 5 μL of 25 μM
Rocext or Rocext R1441H were added to a 96-well thin-walled PCR plate. The
plate was heated in the Real Time PCR Detection System (Mastercycler
Realplex; Eppendorf) from 20 °C to 85 °C, and fluorescence was recorded in
increments of 0.4 °C. The emission wavelength was set at 550 nm.
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